Japan targets 'faster than US FDA' medtech approvals, but reimbursement remains a problem
This article was originally published in SRA
Japanese medical device regulatory conditions are improving fast, at least, that is the intention behind recent ground breaking medtech-specific legislation and a new five-year plan to speed device approvals. But device reimbursement levels remain in need of attention, says Philip Agress, senior vice-president of global strategy and analysis at US medtech industry association AdvaMed.
You may also be interested in...
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.
The RSNA is the next global medtech exhibition and conference event to be run under a virtual format this fall.